If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there.Earlier this week, Sarepta Therapeutics, Inc. (NASDAQ: SRPT ), the commercial stage Pharma that markets and sells four different types of drugs indicated to treat Duchenne ...

Exhibit 99.1 Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2024 Net Product Revenue CAMBRIDGE, Mass., Jan. 13, 2025 — Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported preliminary* fourth quarter and full-year 2024 net product revenue and cash on hand as of December 31, 2024, as part of its presentation today at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, Calif. Financial Update* (preliminary ...

Shares of Sarepta Therapeutics (SRPT) have risen 23% in the past year, significantly outperforming the industry’s 15.7% decline, as shown in the chart below. During this timeframe, the stock has also outdone the broader Medical sector but slightly underperformed the S&P 500 Index. SRPT’s shares are trading above the 50-day moving average.SRPT Stock PerformanceImage Source: Zacks Investment ResearchThe surge in the stock price can be attributed to the encouraging sales performance of Sarepta’s Duchenne muscu ...

Sarepta Therapeutics (SRPT) announced that it has completed enrolment and dosing in the phase III EMERGENE study evaluating its investigational gene therapy, SRP-9003 (bidridistrogene xeboparvovec) for treating limb-girdle muscular dystrophy (LGMD) Type 2E/R4 (LGMD2E/R4, or beta-sarcoglycanopathy).Data from the EMERGENE study is expected in the first half of 2025. If the data is positive, Sarepta intends to submit a regulatory filing seeking accelerated approval for SRP-9003 in the given indication before t ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Shares of Sarepta Therapeutics (SRPT) have gained 14.1% over the past four weeks to close the last trading session at $124.47, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $184.15 indicates a potential upside of 48%.The average comprises 20 short-term price targets ranging from a low of $75 to a high of $217, with a standard deviation of $32.08. While the lowest estimate indi ...

Shares of Sarepta Therapeutics (SRPT) have soared 43% year to date, significantly outperforming the industry’s 6.9% decline. The stock has also underperformed the sector and the S&P 500 during the same period, as shown in the chart below. SRPT’s shares are trading above the 50 and 200-day moving averages.SRPT Stock Outperforms Industry, Sector & S&P 500 Image Source: Zacks Investment ResearchThe surge in the stock price can be attributed to the encouraging sales performance of Duchenne muscular dystrophy (D ...

Shares of Sarepta Therapeutics (SRPT) rose nearly 14% on Tuesday after announcing that it has entered into an exclusive global licensing and collaboration agreement with Arrowhead Pharmaceuticals .ARWR Deal Expands Sarepta’s PipelinePer the deal terms, Sarepta will acquire exclusive rights to Arrowhead’s seven pipeline programs, which include four in active clinical development and the remaining three in preclinical development. These programs are being developed against a broad range of genetic diseases in ...

Shares of Sarepta Therapeutics (SRPT) have gained 0.2% over the past four weeks to close the last trading session at $130.50, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $185.45 indicates a potential upside of 42.1%.The mean estimate comprises 20 short-term price targets with a standard deviation of $31.14. While the lowest estimate of $80 indicates a 38.7% decline from the ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...